Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Chinese Patent Office
US Army

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,711,880

« Back to Dashboard

Summary for Patent: 4,711,880

Title: Crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
Abstract:The invention relates to a novel crystal modification, containing water of crystallization, of disodium 3-amino-1-hydroxypropane-1,1-diphosphonate of the formula ##STR1## and to a process for the manufacture thereof. This modification is suitable for the oral treatment of disorders of the calcium and phosphate metabolism and associated diseases in warm-blooded animals.
Inventor(s): Stahl; Peter H. (Freiburg, DE), Schmitz; Beat (Allschwil, CH)
Assignee: Ciba-Geigy Corporation (Ardsley, NY) Henkel Kommanditgesellschaft auf Aktien (Dusseldorf-Holthausen, DE)
Application Number:06/905,097
Patent Claim Types:
see list of patent claims
Compound; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,711,880

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland3768/84Aug 06, 1984

International Patent Family for Patent: 4,711,880

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina244698► Subscribe
Argentina244697► Subscribe
Cyprus1570► Subscribe
Argentina244696► Subscribe
Argentina240832► Subscribe
Finland852986► Subscribe
Finland79712► Subscribe
Spain8706707► Subscribe
Spain555602► Subscribe
Spain8701188► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus